Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 02 Oct 2014
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Adverse reactions
- Sponsors Bayer
- 20 Oct 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 02 Sep 2005 New trial record.